BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 25473022)

  • 1. The molecular genetics of hereditary and sporadic ovarian cancer: implications for the future.
    Al Bakir M; Gabra H
    Br Med Bull; 2014 Dec; 112(1):57-69. PubMed ID: 25473022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ovarian Cancer in Hereditary Cancer Susceptibility Syndromes.
    Nakonechny QB; Gilks CB
    Surg Pathol Clin; 2016 Jun; 9(2):189-99. PubMed ID: 27241103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mismatch Repair Deficiency in Ovarian Carcinoma: Frequency, Causes, and Consequences.
    Leskela S; Romero I; Cristobal E; Pérez-Mies B; Rosa-Rosa JM; Gutierrez-Pecharroman A; Caniego-Casas T; Santón A; Ojeda B; López-Reig R; Palacios-Berraquero ML; García Á; Ibarra J; Hakim S; Guarch R; López-Guerrero JA; Poveda A; Palacios J
    Am J Surg Pathol; 2020 May; 44(5):649-656. PubMed ID: 32294063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of two poorly prognosed ovarian carcinoma subtypes associated with CHEK2 germ-line mutation and non-CHEK2 somatic mutation gene signatures.
    Ow GS; Ivshina AV; Fuentes G; Kuznetsov VA
    Cell Cycle; 2014; 13(14):2262-80. PubMed ID: 24879340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm.
    Kurman RJ; Shih IeM
    Hum Pathol; 2011 Jul; 42(7):918-31. PubMed ID: 21683865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epigenetic analysis of sporadic and Lynch-associated ovarian cancers reveals histology-specific patterns of DNA methylation.
    Niskakoski A; Kaur S; Staff S; Renkonen-Sinisalo L; Lassus H; Järvinen HJ; Mecklin JP; Bützow R; Peltomäki P
    Epigenetics; 2014 Dec; 9(12):1577-87. PubMed ID: 25625843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Morphologic, Immunophenotypic, and Molecular Features of Epithelial Ovarian Cancer.
    Ramalingam P
    Oncology (Williston Park); 2016 Feb; 30(2):166-76. PubMed ID: 26892153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histologic, molecular, and cytogenetic features of ovarian cancers: implications for diagnosis and treatment.
    Lalwani N; Prasad SR; Vikram R; Shanbhogue AK; Huettner PC; Fasih N
    Radiographics; 2011; 31(3):625-46. PubMed ID: 21571648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.
    Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A
    Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phenotypic heterogeneity of hereditary gynecologic cancers: a report from the Creighton hereditary cancer registry.
    Casey MJ; Bewtra C; Lynch HT; Snyder C; Stacy M; Watson P
    Fam Cancer; 2013 Dec; 12(4):719-40. PubMed ID: 23666231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hereditary ovarian cancer.
    Prat J; Ribé A; Gallardo A
    Hum Pathol; 2005 Aug; 36(8):861-70. PubMed ID: 16112002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Poly (ADP-ribose) polymerase inhibitors: on the horizon of tailored and personalized therapies for epithelial ovarian cancer.
    Ratner ES; Sartorelli AC; Lin ZP
    Curr Opin Oncol; 2012 Sep; 24(5):564-71. PubMed ID: 22759740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The uptake of presymptomatic genetic testing in hereditary breast-ovarian cancer and Lynch syndrome: a systematic review of the literature and implications for clinical practice.
    Menko FH; Ter Stege JA; van der Kolk LE; Jeanson KN; Schats W; Moha DA; Bleiker EMA
    Fam Cancer; 2019 Jan; 18(1):127-135. PubMed ID: 29846880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent progress in the diagnosis and treatment of ovarian cancer.
    Jelovac D; Armstrong DK
    CA Cancer J Clin; 2011; 61(3):183-203. PubMed ID: 21521830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of mutations in BRCA and MMR genes in patients affected with hereditary endometrial cancer.
    Vietri MT; D'Elia G; Caliendo G; Casamassimi A; Federico A; Passariello L; Cioffi M; Molinari AM
    Med Oncol; 2021 Jan; 38(2):13. PubMed ID: 33484353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-risk epithelial ovarian cancer patients for hereditary ovarian cancer.
    Chirasophon S; Manchana T; Teerapakpinyo C
    J Obstet Gynaecol Res; 2017 May; 43(5):929-934. PubMed ID: 28188963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic profiles distinguish different types of hereditary ovarian cancer.
    Domanska K; Malander S; Staaf J; Karlsson A; Borg A; Jönsson G; Nilbert M
    Oncol Rep; 2010 Oct; 24(4):885-95. PubMed ID: 20811668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Oncopathological aspects of BRCA1 and BRCA2 genes inactivation in tumors of ovary, fallopian tube and pelvic peritoneum].
    Škapa P; Dundr P
    Cesk Patol; 2016; 52(4):199-204. PubMed ID: 27869446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes of Incidental Fallopian Tube High-Grade Serous Carcinoma and Serous Tubal Intraepithelial Carcinoma in Women at Low Risk of Hereditary Breast and Ovarian Cancer.
    Chay WY; McCluggage WG; Lee CH; Köbel M; Irving J; Millar J; Gilks CB; Tinker AV
    Int J Gynecol Cancer; 2016 Mar; 26(3):431-6. PubMed ID: 26807643
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinicalpathological characteristics of Lynch syndrome related epithelial ovarian cancer].
    Ma XG; Wang YM; Xue FX; Zhang HY; Sheng HN; Qi Z; Liu GY
    Zhonghua Fu Chan Ke Za Zhi; 2012 Mar; 47(3):201-4. PubMed ID: 22781072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.